^
Association details:
| Biomarker: | JAK2 V617F |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug Class: | Josephin inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2
Published date:
07/29/2021
Excerpt:
Moreover, targeting of JOSD1 leads to the death of JAK2-V617F-positive primary acute myeloid leukemia (AML) cells. These studies provide a novel therapeutic approach to achieving selective targeting of mutated JAK2 signaling in MPN.
DOI:
10.1038/s41375-021-01336-9
